Global Bio-chem Technology's (HKG:0809) attributable profit fell to HK$769.6 million in 2024 from HK$4.22 billion in 2023, according to an annual report filed Wednesday with the Hong Kong bourse.
Earnings per share at the biotechnology firm increased to HK$0.029 from HK$0.291 in the previous year.
Revenue grew to HK$2 billion from HK$1.37 billion a year earlier.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。